Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis.
about
Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stressEffect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failureBrain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individualsTranscriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis.Toll-like receptors in the pathogenesis of alcoholic liver disease.The hepatoadrenal syndrome: a common yet unrecognized clinical condition.Stratification of risk of death in severe acute alcoholic hepatitis using a panel of adipokines and cytokines.Resuscitation of uncontrolled traumatic hemorrhage induced by severe liver injury: the use of human adrenomedullin and adrenomedullin binding protein-1The course of type 1 hepato-renal syndrome post liver transplantation.Pathological mechanisms of alcohol-induced hepatic portal hypertension in early stage fibrosis rat model.High neutrophil-lymphocyte ratio indicates poor prognosis for acute-on-chronic liver failure after liver transplantation.IL-6, through p-STAT3 rather than p-STAT1, activates hepatocarcinogenesis and affects survival of hepatocellular carcinoma patients: a cohort studyInsulin-like growth factor I improves intestinal barrier function in cirrhotic rats.Advances in alcoholic liver disease: An update on alcoholic hepatitisHow to modulate inflammatory cytokines in liver diseases.Anti-CD163-dexamethasone conjugate inhibits the acute phase response to lipopolysaccharide in rats.Lipopolysaccharide-Induced Neutrophil Dysfunction Following Transjugular Intrahepatic Portosystemic Stent Shunt (TIPSS) Insertion is Associated with Organ Failure and Mortality.Pharmacotherapy of acute alcoholic hepatitis in clinical practice.Alcohol, psoriasis, liver disease, and anti-psoriasis drugs.The effects of alcohol on the metabolism and toxicology of anti-psoriasis drugs.Prognosis and treatment of patients with acute alcoholic hepatitis.Renal dysfunction in cirrhosis is not just a vasomotor nephropathy.Emerging hepatic syndromes: pathophysiology, diagnosis and treatment.Assessment of Hepatic Impairment and Implications for Pharmacokinetics of Substance Use Treatment.Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver.Expression of TNF-alpha and VEGF in the esophagus of portal hypertensive rats.Tumor necrosis factor alpha signaling in the development of experimental murine pre-hepatic portal hypertension.Hepatic Overlap Syndrome Improved With Infliximab.Selective Intestinal Decontamination in Portal Hypertension[Management of severe alcoholic hepatitis].A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis.Post-Transcriptional Regulation of Hepatic DDAH1 with TNF Blockade Leads to Improved eNOS Function and Reduced Portal Pressure In Cirrhotic Rats.Beyond scoring: a modern interpretation of disease progression in chronic liver disease.
P2860
Q27023122-E9482F9C-6F80-4C17-956E-3135600CC319Q27499349-7A8B19DA-1822-4375-81A8-27FEE88B8142Q33614467-CBEA3460-7BFE-42F4-85F4-10E484872CB1Q33783707-84110BCF-AE9D-4610-B22D-0B2FB9AD545CQ34106192-A5AB1874-84A7-43E3-8A7B-236F70B15F03Q34340237-BC921725-9329-474F-A8EA-3040C8A1AE7FQ34574219-913B5A04-4955-41DE-AD81-22D2AF014D5DQ35113976-956EA234-0A32-40BC-A18E-1183CF57381EQ35160366-5ECC33C2-A668-4017-B577-9ADF30437586Q35165971-E407B406-1EF8-4891-9928-78A11B17333AQ35188626-A3953617-1C49-40FC-BD8F-C5CA5F97AE74Q35584162-B08C5420-9D95-4C00-BC79-D0DA2498D3A3Q35768917-7CB4D653-E9B6-4588-8E7B-B7B7FB0C422EQ36269638-0ECA3027-2C26-4320-9127-3A0832986C53Q36619707-90FDB4D5-E8D7-4D8B-9077-139D007EBFDFQ37014721-96E366E6-28B7-4A20-B384-0A8A5C765C59Q37554365-FD355002-22B5-43D3-A398-A7B969BED35CQ37617944-A43E45DC-7287-4F56-BA02-59144573B2B5Q37946497-B8444D05-E4E4-46FC-A90E-F711778C1A4EQ38010769-A635E427-2380-4D95-B44B-C6C1368EDD16Q38203313-75FA7B23-CEEE-4672-B174-DEC0B0A0405CQ38258146-F2454F2C-D53B-4631-A9C9-47860A70061CQ38858262-4A1245E7-7D62-4595-9ADB-5273947EAE2EQ38927192-09AA5A6B-4C93-4012-BE5F-C1A990C019F5Q40202250-CC82B66A-D07C-4DE7-981D-FD66DB86DFCFQ42126959-F69F6F2C-9928-4D7B-AF58-179F563D0131Q42287772-8AEBA5E5-899A-48F5-8036-40FCF13DADADQ42318655-17AB7CBA-EAB6-48B2-93A6-1D42E2A3F953Q42321783-6C41D5CA-2FD3-40FD-888F-0B4ED627CFCBQ44181725-6C1D3DEB-18AA-4A9E-9650-AE69418B3AEEQ44700481-FBE5175B-E723-4E80-A409-2D8BB66BDC30Q47134026-AF623B76-97D1-4A82-BC53-6FB8B102312CQ51018265-07F1A976-4672-4CC8-ABEF-C199A387B71F
P2860
Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Tumour necrosis factor alpha i ...... ements in alcoholic hepatitis.
@ast
Tumour necrosis factor alpha i ...... ements in alcoholic hepatitis.
@en
type
label
Tumour necrosis factor alpha i ...... ements in alcoholic hepatitis.
@ast
Tumour necrosis factor alpha i ...... ements in alcoholic hepatitis.
@en
prefLabel
Tumour necrosis factor alpha i ...... ements in alcoholic hepatitis.
@ast
Tumour necrosis factor alpha i ...... ements in alcoholic hepatitis.
@en
P2093
P2860
P356
P1433
P1476
Tumour necrosis factor alpha i ...... gements in alcoholic hepatitis
@en
P2093
P2860
P304
P356
10.1136/GUT.52.8.1182
P407
P577
2003-08-01T00:00:00Z